Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
djHmgs9MWxD7s1L1
